Therapeutic potential for P2Y₂ receptor antagonism

Area of Science:

• Pharmacology
• Molecular Biology
• Drug Discovery

Background:

• G protein-coupled receptors (GPCRs) are crucial drug targets, with P2Y receptors being of significant therapeutic interest.
• While P2Y12 receptor antagonists are established drugs, P2Y2 receptor (P2Y2R) antagonism remains underexplored due to a lack of selective agents.
• Previous studies relied on genetic methods to uncover P2Y2R's role in various diseases, including inflammatory, fibrotic, renal, and infectious conditions, as well as cancer.

Purpose of the Study:

• To review the unique characteristics of P2Y2R, including its involvement in five distinct signaling pathways.
• To discuss the impact of P2Y2R antagonists, highlighting the recent development of AR-C118925.
• To examine the growing evidence linking P2Y2Rs to disease pathogenesis, particularly using AR-C118925 in preclinical models.

Main Methods:

• Literature review of P2Y2R characteristics and signaling pathways.
• Analysis of studies employing P2Y2R antagonists, with a focus on AR-C118925.
• Examination of preclinical data evaluating AR-C118925 in various disease models.

Main Results:

• P2Y2R exhibits unique signaling properties, including engagement with canonical Gαq protein signaling.
• The availability of AR-C118925, a potent and selective P2Y2R antagonist, facilitates robust investigation.
• Emerging evidence implicates P2Y2Rs in the pathogenesis of diverse diseases, with preclinical studies showing therapeutic potential for antagonism.

Conclusions:

• P2Y2R antagonism represents a largely untapped therapeutic avenue.
• AR-C118925 is a key tool for advancing the understanding and therapeutic application of P2Y2R antagonism.
• Further research utilizing AR-C118925 is crucial for validating P2Y2R antagonism in treating a range of diseases.